Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Obstet Gynecol ; 140(4): 704, 2022 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-36356251
2.
Obstet Gynecol ; 139(4): 687-691, 2022 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-35271511

RESUMO

This commentary serves to raise awareness for health care professionals about the potential risks of accidental ingestion of flibanserin tablets by children. Flibanserin was approved by the U.S. Food and Drug Administration (FDA) for the treatment of acquired generalized hypoactive sexual desire disorder in premenopausal women. Since its approval in 2015, the FDA has identified five reports of serious accidental ingestion by toddlers. All five children, boys with ages ranging from 18 months to 2 years, presented with central nervous system and respiratory depression, and two of them required intubation. A combination of hypertension, hyperthermia, and seizure-like activity was also seen in four of the five children. The clinical manifestation resembles serotonin syndrome (eg, tachycardia, hypertension, and muscle stiffness). As flibanserin use increases, greater awareness by health care professionals regarding the risk of accidental pediatric ingestion is needed to facilitate preventative counseling for patients with young children.


Assuntos
Hipertensão , Disfunções Sexuais Psicogênicas , Benzimidazóis , Sistema Nervoso Central , Criança , Pré-Escolar , Depressão , Ingestão de Alimentos , Feminino , Pessoal de Saúde , Humanos , Masculino , Disfunções Sexuais Psicogênicas/tratamento farmacológico
3.
Am J Obstet Gynecol ; 225(1): 21-32, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34215352

RESUMO

Obstetrical healthcare providers frequently field questions about the safety of medications recommended or prescribed to their pregnant patients. Most women use as least 1 medication during pregnancy; however, there is little information about the safety or appropriate dosing of many medications during this phase of life. In addition, the development of drugs for use in pregnant women trails behind the development of drugs intended for other sectors of the population. Our goal is to inform the obstetrics community about the US Food and Drug Administration authority and their role in approving drugs for marketing. We begin with the statutes that led to the creation of the Food and Drug Administration and its current organization. We then cover drug development and the Food and Drug Administration review process, including the role of the advisory committee. The different types of drug approvals are discussed, with some specific examples. Finally, we enumerate the drugs specifically approved for use in obstetrics and contrast them with drugs commonly used by pregnant women and drugs used "off-label" during pregnancy. The Food and Drug Administration is committed to protecting and advancing the public health of pregnant women by guiding the development and ensuring the availability of effective and safe therapeutics for obstetrical indications and for medical conditions during pregnancy. We hope this review will inspire more research addressing drug use during pregnancy.


Assuntos
Aprovação de Drogas , Gravidez , Medicamentos sob Prescrição , United States Food and Drug Administration , Animais , Ensaios Clínicos como Assunto , Aprovação de Drogas/legislação & jurisprudência , Aprovação de Drogas/estatística & dados numéricos , Feminino , Feto/efeitos dos fármacos , Humanos , Lactação , Complicações na Gravidez/tratamento farmacológico , Medição de Risco , Teratogênicos , Estados Unidos
5.
Obstet Gynecol ; 130(4): 913-914, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-28937560
6.
Obstet Gynecol ; 129(6): 1054-1058, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28486375

RESUMO

This commentary serves to raise health care provider awareness about the regulatory status and available evidence regarding domperidone for insufficient lactation. Breastfeeding provides significant health benefits for mothers and infants, and insufficient milk production remains the most common reason for early weaning. Domperidone, a dopamine receptor antagonist that may increase milk production, is not approved for any human use in the United States. It is approved in some countries for certain gastrointestinal disorders, but is not approved in any country for lactation enhancement. Domperidone is associated with serious cardiac arrhythmias. The U.S. Food and Drug Administration (FDA) issued an import alert in 2004, updated in 2012, explaining that the importation of domperidone is illegal with limited exceptions, including when imported pursuant to an investigational new drug application. The FDA also issued a public safety warning regarding the use of domperidone for lactation. Nonetheless, domperidone is sometimes being obtained illegally and used in attempts to increase milk production in lactating mothers. There is limited quality evidence for the effectiveness of domperidone for lactation enhancement. In contrast, considerable information exists on domperidone's cardiac risks including QT prolongation, torsades de pointes, and sudden cardiac death, including among lactating women. In light of limited efficacy data that do not offset safety concerns from a public health perspective, we continue to caution against using domperidone for lactation enhancement. Research and drug development are needed to address the significant unmet medical need for lactation disorders.


Assuntos
Aleitamento Materno , Domperidona/farmacologia , Galactagogos/farmacologia , Lactação/efeitos dos fármacos , Padrões de Prática Médica , Domperidona/efeitos adversos , Feminino , Galactagogos/efeitos adversos , Humanos , Obstetrícia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA